オプションチェーンは、CVS Healthの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、CVS Healthの市場センチメントを評価します。.

CVS Health (NYSE:CVS) 株価情報, オプションチェーン

CVS HEALTH CORP

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has risen 21.14% since its last report. The company recently reported that it has 18.71 million shares sold short, which is 1.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.14 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752080444_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 10.36%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is CVS Health Gaining or Losing Market Support?

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its head above parity. Nevertheless, the statistical winds may point to an eventual recovery which options traders could potentially exploit.
Fundamentally, in the post-pandemic era, sentiment toward Eli Lilly skyrocketed thanks to its <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">weight-loss drug</a>. In 2023, the U.S. Food and Drug Administration (FDA) approved the Zepbound (tirzepatide), the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. An injectable prescription medication that helps adults with other weight-related problems, Zepbound's clinical trials showed promising results.
Thanks to this early success, Eli Lilly and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) effectively formed a duopoly in the weight-loss market. While this reality contributed to a significant valuation surge, competition started to heat up last year. With major pharmaceuticals like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Roche Holding Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announcing advancements in the <a href="https://www.benzinga.com/general/biotech/24/07/39849867/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-wont-be-dominated-by-just-2">development of obesity-fighting drugs</a>, LLY stock entered into a frustrating consolidation channel.
Still, with the pharmaceutical giant incurring an extended period of red ink in the market, JPMorgan analyst Chris Schott is essentially making the case that Eli Lilly is undervalued. Specifically, prescriptions for Zepbound and Mounjaro (an injectable <a href="https://www.lilly.com/news/media/media-kits/mounjaro">medicine</a> for adults with type 2 diabetes) are running ahead of expectations in the second quarter. As such, this performance may allow the pharmaceutical to beat and raise guidance throughout 2025.
Even with the <a href="https://www.benzinga.com/content/45261458/is-eli-lilly-a-buy-after-weak-earnings-and-cvs-novo-partnership">formulary change</a> by CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) putting around 200,000 patients at risk of losing access, Schott states that Eli Lilly's market share — which stands at about 70% to 75% of new patients — and strong momentum may help the company easily absorb the impact.
<h2 class="wp-block-heading">Statistical Backdrop Could Point To A Recovery In LLY Stock</h2>
Although the fundamental narrative of LLY stock is intriguing, it may also be a presuppositional leap. Essentially, the conclusion that LLY is undervalued is already embedded in the premise (that the market is not fully pricing in the good news for Eli Lilly).
If one thinks about it, it's an extraordinary claim. LLY stock routinely ranks among the most actively traded securities. That the market is somehow mispricing the pharmaceutical giant is an assertion that requires extraordinary evidence. In my opinion, if such evidence exists, it will likely materialize in the statistical realm as it's the arena that few (if any) analysts venture into.
A significant barrier to statistical analysis of the financial markets is the deployment of continuous scalar signals, such as share price or various valuation ratios. Because these signals are non-stationary, it's difficult (if not outright impossible) to extract meaningful insights based on the frequency of past analogs. Especially for highly traded securities like LLY stock, the measurement metrics constantly fluctuate.
To remedy this problem, we can impose stationarity by converting scalar signals into discrete states. For analyzing securities, converting share price into market breadth or sequences of accumulative and distributive sessions carries significant advantages. First, market breadth is essentially a representation of demand and demand is effectively binary. Second, clusters of binary codes can form distinct behavioral states, which can then serve as past analogs for extracting forward probabilities.
As an example, in the trailing two months, the price action of LLY stock can be interpreted as a "6-4-D" sequence: six up weeks, four down weeks, with a negative trajectory across the 10-week period. Admittedly, this process pancakes LLY's magnitude dynamism into a simple binary code. But the benefit is that this code can be easily segregated into distinct market profiles. From there, we can observe the likelihood of transition from one state to another.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-975331" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
With the above framework, we can identify that since January 2019, the 6-4-D sequence has materialized 38 times. From past analogs, we can also determine that in 68.42% of cases, the following week's price action results in upside, with a median return of 2.47%.
Accounting for the volatility on Monday, a realistic target over the next three weeks — assuming that the bulls gain and maintain control of the market — is just under the $800 level.
<h2 class="wp-block-heading">Playing The Odds With Eli Lilly</h2>
Based on the market intelligence above, bold speculators may consider the 785/790 bull call spread expiring Aug. 1. This transaction involves buying the $785 call and simultaneously selling the $790 call, for a net debit paid of $255 (the most that can be lost in the trade). Should LLY stock rise through the short strike price ($790) at expiration, the maximum reward is $245, a payout of 96%.
To be sure, the 780/790 bull spread expiring on the same day offers a payout of nearly 113%. However, the net debit required is $470, which puts significantly more capital at risk for only a modest increase in payout. Therefore, the 785/790 call spread is arguably more tempting.
Either way, both transactions require LLY stock to hit or exceed $790 on Aug. 1, which empirically appears to be a reasonable target. As a baseline, the chance that a long position in LLY will be profitable on any given week is quite high at 60.29%. However, the market's response to the 6-4-D sequence amplifies the odds in favor of the bullish speculator, thus incentivizing a debit-based strategy.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46253955/khc-stock-bearish-pressure-statistical-reversal">Options Corner: Why Kraft Heinz Could Flip The Script On The Bears</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Long Ideas

Options

RHHBY

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.
What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent across plans. &#8220;Coverage is not the same as access,&#8221; said Beverly Tchang, a New York-based physician who advises both Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), reported <a href="https://apnews.com/article/wegovy-zepbound-obesity-drugs-coverage-access-142e234c16df4443e8f66c27d01f44e2#">the</a> Associated Press.
GLP-1 receptor agonists continue driving substantial revenue for both drugmakers. Zepbound generated $2.3 billion in U.S. first-quarter sales, while Wegovy contributed nearly $1.9 billion with approximately 200,000 weekly prescriptions domestically.
Insurance coverage varies dramatically by provider and plan type. Novo Nordisk reports that 85% of covered U.S. patients pay $25 or less monthly. However, most state Medicaid programs and Medicare exclude obesity coverage, forcing patients to shoulder hundreds in out-of-pocket costs monthly, according to the report.
See Also: <a href="https://www.benzinga.com/markets/large-cap/25/07/46269182/ai-assistants-could-break-amazons-60-billion-retail-media-business-warns-vc-its-not-just-search-at-google-its-search-everywhere">AI Assistants Could Break Amazon&#8217;s $60 Billion Retail Media Business, Warns VC: &#8216;It&#8217;s Not Just Search At Google — It&#8217;s Search Everywhere&#8217;</a>
Why It Matters: The regulatory landscape remains complex regarding compounded versions. Despite FDA determinations that drug shortages ended, compounding pharmacies continue selling cheaper alternatives under personalization exceptions.
Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) offers compounded semaglutide starting at $165 monthly, leading to legal challenges from Eli Lilly.
Recent pricing trends show that both companies reduced uninsured patient costs by several hundred dollars from initial launch prices. However, $500 monthly represents approximately 14% of the average U.S. per-capita income at $43,000 annually.
Long-term adherence data reveals persistence challenges that could impact market expansion. Real-world studies show only 8.1% of patients maintained GLP-1 obesity therapy after three years, though one-year persistence for Wegovy <a href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows">improved from 33.2% in 2021 to 62.7% in 2024</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46268630/alphabet-backed-drug-discovery-firm-nears-human-trials-of-ai-developed-remedies-says-president-the-next-big-milestone-is">Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: &#8216;The Next Big Milestone Is…&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tobias Arhelger / Shutterstock.com

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.79%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On June 26, Pfizer announced positive topline Phase 3 results for HYMPAVZI&#x2122; in Hemophilia A or B with inhibitors.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">latest PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="917" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png" alt="" class="wp-image-971905" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-768x688.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.99%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $82 to $84 on May 12, 2025. This analyst has an accuracy rate of 67%.</li>
<li>RBC Capital analyst Ben Hendrix maintained an Outperform rating and boosted the price target from $74 to $81 on May 5, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: CVS Health will hold a conference call on Thursday, July 31 to discuss second quarter 2025 financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">CVS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="912" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png" alt="" class="wp-image-971907" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.93%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On July 2, the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck's new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for Winrevair (sotatercept-csrk).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="911" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png" alt="" class="wp-image-971910" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-768x697.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Across the recent three months, 10 analysts have shared their insights on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CVS Health, presenting an average target of $79.0, a high estimate of $84.00, and a low estimate of $71.00. This upward trend is evident, with the current average reflecting a 8.97% increase from the previous average price target of $72.50.
<img src="https://www.benzinga.com/files/images/story/2025/1751310042_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive CVS Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CVS Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CVS Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CVS Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>Get to Know CVS Health Better</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>CVS Health: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining CVS Health's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.96% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CVS Health's net margin excels beyond industry benchmarks, reaching 1.88%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.33%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CVS Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.7%, the company may face hurdles in achieving optimal financial performance.
Debt Management: CVS Health's debt-to-equity ratio stands notably higher than the industry average, reaching 1.06. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: CVS Health Through The Eyes Of 10 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>B of A Securities raised Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) price target from $20 to $23. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Hewlett Packard Enterprise shares closed at $18.41 on Friday. <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS cut the price target for United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from $410 to $385. UBS analyst Ashwani Verma maintained a Buy rating. United Therapeutics shares closed at $284.27 on Friday. <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital slashed Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) price target from $7 to $3. BMO Capital analyst John McNulty downgraded the stock from Market Perform to Underperform. Tronox shares closed at $5.64 on Friday. <a href="https://www.benzinga.com/quote/TROX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup boosted the price target for Air Products and Chemicals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) from $310 to $320. Citigroup analyst Patrick Cunningham maintained a Buy rating. Air Products shares closed at $282.35 on Friday. <a href="https://www.benzinga.com/quote/APD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays increased the price target for Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from $67 to $80. Barclays analyst Ramsey El-Assal maintained an Overweight rating. Affirm Holdings shares closed at $68.06 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) price target from $81 to $85. Raymond James analyst RJ Milligan maintained an Outperform rating. Boyd Gaming shares settled at $79.02 on Friday. <a href="https://www.benzinga.com/quote/BYD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) price target from $100 to $120. JP Morgan analyst Cory Carpenter maintained an Overweight rating. Roblox shares closed at $105.59 on Friday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) price target from $74 to $80. Jefferies analyst Brian Tanquilut maintained a Buy rating. CVS Health shares closed at $68.49 on Friday.  <a href="https://www.benzinga.com/quote/CVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted the price target for J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) from $130 to $140. Truist Securities analyst Lucas Pipes maintained a Hold rating. J.B. Hunt Transport shares settled at $145.34 on Friday. <a href="https://www.benzinga.com/quote/JBHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim increased The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $120 to $140. Guggenheim analyst Michael Morris maintained a Buy rating. Disney shares closed at $122.34 on Friday. <a href="https://www.benzinga.com/quote/dis/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DIS/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-1024x587.png" alt="" class="wp-image-967350" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a> </li>
</ul>
Photo via Shutterstock

AFRM

JBHT

RBLX

TROX

UTHR

Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday

Jefferies analyst Brian Tanquilut maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $74 to $80.

Jefferies Maintains Buy on CVS Health, Raises Price Target to $80

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/" title="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>
&nbsp;

General

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

Shares of CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) are trading higher Thursday afternoon. The stock is rising as a Republican legislative package targeting major tax and healthcare changes faces a considerable obstacle in the U.S. Senate.
What To Know: According to a <a href="https://www.usatoday.com/story/news/politics/2025/06/26/trump-tax-bill-medicaid-setback-senate/84367717007/">report</a> from USA TODAY, the Senate&#8217;s parliamentarian, Elizabeth MacDonough, ruled on June 26 that several key provisions aimed at overhauling Medicaid could not be included in the bill under the Senate&#8217;s budget reconciliation rules. 
The provisions, which included work requirements and restrictions for non-citizens, were designed to reduce federal spending on the health insurance program for lower-income families.
The ruling is being viewed as a major blow to the bill&#8217;s prospects as Democrats celebrated the decision. &#8220;Democrats fought and won, striking health care cuts from this bill that would hurt Americans walking on an economic tightrope," Senator Ron Wyden told USA TODAY.
Read Also: <a href="https://www.benzinga.com/news/politics/25/06/46042224/donald-trump-jr-joins-mark-cuban-in-slamming-elizabeth-warren-on-healthcare-pricing">Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing</a>
Why This Matters: This legislative setback is likely causing CVS stock to rise because a significant portion of the company&#8217;s revenue is tied to the stability of the American healthcare system, including programs like Medicaid. 
The proposed cuts to Medicaid, had they been successful, could have resulted in millions of Americans losing their health insurance coverage. This would directly translate to fewer prescriptions being filled at CVS pharmacies and a reduction in the number of members in the Aetna health insurance plans it owns. 
By blocking these cuts, the immediate threat to this substantial revenue stream is removed, providing investors with greater confidence in CVS&#8217;s future earnings and financial stability.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CVS shares are trading higher by 1.9% to $67.62 Thursday afternoon. The stock has a 52-week high of $72.51 and a 52-week low of $43.56.
Read Also: <a href="https://www.benzinga.com/news/health-care/25/06/46056665/unitedhealth-cvs-among-major-insurers-to-fast-track-prior-authorizations-will-it-cut-profits-even-more">UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?</a>
<h2 class="wp-block-heading">How To Buy CVS Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in CVS Health&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

CVS Health Stock Jumps As GOP Health Bill Stalls

WIIM

Shares of health insurers are trading higher as a Republican legislative package targeting tax and healthcare changes faces obstacles in the US Senate.

<a href="https://www.klfy.com/louisiana/landry-murrill-to-host-news-conference-will-announce-major-legal-action-against-cvs/#:~:text=In%20a%20statement%2C%20CVS%20said,law%2C%E2%80%9D%20the%20statement%20read.">https://www.klfy.com/louisiana/landry-murrill-to-host-news-conference-will-announce-major-legal-action-against-cvs/#:~:text=In%20a%20statement%2C%20CVS%20said,law%2C%E2%80%9D%20the%20statement%20read.</a>
&nbsp;

Legal

CVS Health Responds To Louisiana Attorney General Liz Murrill Lawsuits; Says "The Claims Are Without Merit And (We) Will Defend Ourselves Vigorously"; "Our Communication With CVS Customers, Patients And Members Of The Community Was Consistent With The Law"

<a href="https://x.com/AGLizMurrill/status/1937585255646642652" title="https://x.com/AGLizMurrill/status/1937585255646642652">https://x.com/AGLizMurrill/status/1937585255646642652</a>

Attorney General Liz Murrill Posts On X "Today, I've filed 3 separate lawsuits against CVS for unfair, deceptive, and unlawful practices that have harmed Louisiana patients, independent pharmacies, and the public at large. The State is seeking both injunctive relief and restitution."

<a href="https://www.wsj.com/politics/policy/lawmakers-seek-to-close-va-loophole-that-funnels-billions-to-private-medicare-insurers-cfbe0b19">https://www.wsj.com/politics/policy/lawmakers-seek-to-close-va-loophole-that-funnels-billions-to-private-medicare-insurers-cfbe0b19</a>

ELEV

'Lawmakers Seek to Close VA Loophole That Funnels Billions to Private Medicare Insurers'- WSJ

Leading health insurers announced on Monday that they have agreed to a set of measures aimed at connecting patients to care faster and <a href="https://www.benzinga.com/money/insurance">reducing paperwork for providers</a>.
What To Know: According to <a href="https://www.cnbc.com/2025/06/23/prior-authorizations-us-insurers-to-change-approval-process.html">CNBC</a>, several major U.S. health insurers — including CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) — will voluntarily speed up and simplify the prior authorization process, which often causes delays and frustrations for patients <a href="https://www.benzinga.com/news/health-care/25/06/45845302/unitedhealth-eyes-retreat-from-latin-america-after-8-3-billion-loss">and healthcare providers. </a>
Read Next: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46030182/circle-stock-rockets-540-cathie-wood-says-weve-just-begun?utm_source=articleShare">Circle Stock Rockets 540%: Cathie Wood Says &#8216;We&#8217;ve Just Begun&#8217;</a>
These changes, coordinated through the industry group AHIP, will apply to commercial insurance as well as some Medicare and Medicaid plans, potentially benefiting 257 million Americans.
Key steps include:
<ul class="wp-block-list">
<li>Setting a common standard for submitting electronic prior authorization requests by 2027.</li>
<li>By that time, at least 80% of electronic requests with all required documents will receive real-time responses.</li>
<li>Reducing the number of services that require prior authorization by 2026.</li>
<li>Streamlining processes to lessen the administrative burden on doctors and hospitals, many of whom still use paper forms.</li>
</ul>
Why It Matters: The insurers acknowledged that while these changes could increase patients' use of care, possibly affecting profits, they are necessary to improve the healthcare system.&nbsp;
Healthcare stocks are already underperforming <a href="https://www.benzinga.com/news/health-care/25/06/45997946/stock-market-strategy-investing-analysis-healthcare-stocks-united-health">the broader market</a> by the widest margin since 2008, as investors favor technology and AI companies.&nbsp;
The Healthcare Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) now trades at its lowest value relative to the S&amp;P 500 in over a decade — a 40% drop from 2015 levels.
History shows that such deep undervaluation in healthcare often leads to strong rebounds, as seen after similar slumps in 2001 and 2008. Major companies like UnitedHealth, Eli Lilly and Merck have all posted steep declines this year.
Despite recent struggles, analysts are optimistic: 59 out of 60 healthcare companies in XLV have 12-month price targets above current prices, with an average expected upside of 17%.&nbsp;
Read Next:<a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest?utm_source=articleShare">&nbsp;</a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest?utm_source=articleShare">Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill: Latest</a>&nbsp;</li>
</ul>
Image: Shutterstock&nbsp;

Large Cap

Movers

UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?

CVS Health Unit Aetna Unveils New Strategy To Cut Red Tape in Healthcare With Bundled Authorizations And On-Site Nurse Support

Donald Trump Jr. has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)&#8217;s approach to healthcare pricing.
Despite their political differences, Trump Jr. and Cuban found a common point of contention in Warren&#8217;s healthcare pricing strategy. They criticized the senator for not addressing&nbsp;the role of pharmacy benefit&nbsp;managers (PBMs) in escalating drug costs.
Warren had previously argued&nbsp;that the tax system was&nbsp;&#8220;rigged&#8221;&nbsp;because large pharmaceutical companies like&nbsp;Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) often escape federal taxes while charging exorbitant prices for their drugs. 
She wrote on X saying that the "highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Big Pharma companies like Johnson &amp; Johnson and Pfizer charge Americans the highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves. Why? Because our tax system is rigged. Now, Republicans want to make it worse. I&#39;m fighting back. <a href="https://t.co/k7dFrXBneX">pic.twitter.com/k7dFrXBneX</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1935443373487440373?ref_src=twsrc%5Etfw">June 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban countered this by stating that PBMs, not pharmaceutical companies, are the ones controlling and manipulating drug pricing.
Also Read: <a href="https://www.benzinga.com/news/25/01/43245984/cuban-on-musk-i-have-no-problem-throwing-elon-under-the-bus-but-ill-save-it-for-when-its-truly-deser">Cuban on Musk: &#8216;I Have No Problem Throwing Elon Under the Bus, but I&#8217;ll Save It for When It&#8217;s Truly Deserved&#8217;</a>
Trump Jr. publicly supported Cuban&#8217;s viewpoint on X, despite Cuban&#8217;s well-known opposition to President Trump. This unexpected agreement highlights the growing concern over the role of PBMs in healthcare pricing.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Didn't think I'd be RTing Mark for a while, but he's 100% right on this issue. <a href="https://t.co/ofraK5IFQk">https://t.co/ofraK5IFQk</a>
&mdash; Donald Trump Jr. (@DonaldJTrumpJr) <a href="https://twitter.com/DonaldJTrumpJr/status/1935817600891601345?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
PBMs have been facing increasing scrutiny from federal regulators and lawmakers due to their influence on healthcare pricing. 
In 2020, the Federal Trade Commission released a report criticizing PBMs for imposing unfair terms on independent pharmacies, thereby favoring large corporate pharmacies like&nbsp;CVS&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
The public criticism from Trump Jr. and Cuban underscores the growing debate over the role of PBMs in healthcare pricing. 
Warren&#8217;s focus on pharmaceutical companies, while not entirely misplaced, overlooks the significant influence of PBMs in determining drug prices.
The Federal Trade Commission&#8217;s report from last year further highlights the need for regulatory scrutiny of PBMs. As the debate continues, it remains to be seen how lawmakers will address the issue of healthcare pricing and the role of PBMs in the future.
Read Next
<a href="https://www.benzinga.com/news/politics/25/06/45829489/mark-cuban-reacts-to-elon-musk-donald-trump-feud">Mark Cuban Reacts to Elon Musk-Donald Trump Feud</a>
Image: Shutterstock/lev radin

Politics

Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing

We have discussed why I favor real estate and Real Estate Investment Trusts. Since 1972, REITs have outperformed the major indexes. According to CEM Benchmarking, publicly traded real estate has outperformed every asset class except private equity since 1998. REITs have an excellent track record of paying and growing dividends.
Most people would rather chase stories than be the landlord and lender. I know far more wealthy lenders and landlords than I do rich dreamers.
Right now, most investors either hate real estate or simply do not think about it. The instant experts of the internet are convinced that real estate is heading to zero and will crash the banking system. They believe only bitcoin and AI stocks are worth buying. That is not going to happen.
Make your own call on bitcoin and AI. But consider this: who needs real estate?
Bitcoin and AI companies and their employees do. They need office space. They live somewhere. They shop at stores, pharmacies, and frequent gas stations and convenience stores. They visit doctors and labs. They travel to conferences usually held in hotels.
Those that actually manufacture products will eventually need warehouse and logistics space. Bitcoin miners need physical locations to house all those computers.
The majority of high-tech startups are going nowhere, but the people involved will still interact with real estate and make landlords wealthy regardless of how their ventures turn out.
I am not the only one who likes real estate at current prices.
&nbsp;I am seeing insiders who run these REITs (people who know the market better than anyone) begin making open market purchases of their own stocks.
John Rakolta Jr. is Chairman of Walbridge, one of the largest privately owned construction companies in the United States. Walbridge is a top U.S. builder of automotive and manufacturing facilities and has achieved considerable market diversity through expansion into the hyperscale data center market. He is also a Director of Agree Realty and has been aggressively buying shares in the open market recently.
While the instant experts of the internet scream &#8220;retail apocalypse&#8221; and predict the death of brick-and-mortar stores, Agree Realty (Ticker: ADC) has not only survived but thrived by completely rewriting the playbook. Agree Realty represents everything I look for in a long-term holding: contrarian thinking, exceptional management, fortress-like financials, and a business model that generates predictable cash flows in an unpredictable world.
In 2010, while everyone was fleeing retail real estate like it was radioactive, Agree Realty management team made a prescient decision that would define the company future. They launched their acquisition platform with a laser focus on &#8220;e-commerce resistance,&#8221; a concept largely ignored by the investment community at the time.
Consider that timing. This was just two years after the financial crisis, with Amazon retail dominance becoming increasingly apparent and traditional retailers closing stores left and right. Most investors and REITs were fleeing the sector. But Joey Agree and his team saw something different. They understood that certain types of retail were not going to disappear. They were going to evolve and become more essential than ever.
This was not just lucky timing. It marked the beginning of what would become one of the most successful strategic repositioning stories in REIT history.
Agree management articulated something Wall Street was missing: the emergence of the omni-channel economy. As Joey Agree explained in 2016, &#8220;Every retailer in the country is going to have to have billions of dollars, national retailers, to experiment, to test and eventually effectuate a true omni-channel experience because you cannot be an e-commerce-based retailer or just a brick-and-mortar-based retailer today. It does not work.&#8221;
This was not corporate speak. It was a fundamental insight that would prove prophetic. While others saw physical stores as dinosaurs, Agree saw them as critical infrastructure for the new retail economy. Stores were not just selling locations anymore; they were fulfillment centers, pickup points, showrooms, and customer experience hubs all rolled into one.
The company &#8220;RETHINK RETAIL&#8221; campaign was not marketing fluff. It was a declaration of war against conventional wisdom.
Let me walk you through some of Agree greatest hits, because this is where the company investment acumen really shines:
Tractor Supply Company (Ticker: TSCO) &#8211; Agree first acquired a Tractor Supply location in Q3 2013 when the company was still relatively unknown outside rural markets. Management saw something special: a retailer with no national competition serving the growing rural lifestyle market with products that could not easily be replicated online.
By Q2 2016, management was saying: &#8220;While neither Tractor Supply Company nor Hobby Lobby maintains a public credit rating, both possess investment-grade quality financials with very strong balance sheets.&#8221; They were ahead of the rating agencies by years.
By Q3 2018, their conviction was proven right: &#8220;We have a fantastic relationship with their real estate team. The business is really thriving. They have no national competition. They also have the highest-rated e-commerce website of any retailer.&#8221;
Today, after acquiring over 115 locations since 2013, Tractor Supply is Agree second-largest tenant at 4.9% of base rent. More importantly, TSCO was upgraded to investment grade (BBB by S&amp;P and Baa1 by Moody) in October 2020, validating Agree early assessment of the company credit quality.
Gerber Collision In 2014, Agree identified and met with The Boyd Group, parent company of Gerber Collision, recognizing early that this was a company positioned to consolidate a highly fragmented auto collision repair market. Their first acquisition came in Q3 2017.
By Q1 2018, management was already calling Gerber &#8220;the premier auto collision operator in the United States&#8221; and committed to working with them across all three growth platforms. By Q1 2022, they were describing their strategy as &#8220;identifying early on a retailer that we thought was in a tremendous position to access a fragmented space and had the balance sheet capabilities to do so.&#8221;
The result? Agree built a preferred development relationship with Gerber, developing over 20 locations to support their organic growth. Today, Gerber Collision is their 12th largest tenant with over 95 locations representing 2.3% of base rent.
Sunbelt Rentals First acquired in Q4 2015, Sunbelt Rentals represented Agree&#8217;s bet on the shift from equipment ownership to rental in the construction industry. As management explained in Q4 2019: &#8220;the only investment-grade operator in the country. If you look at the equipment ownership versus rental in this country&#8230; it is very, very low relative to Western Europe. And so, there&#8217;s a big opportunity in this country for equipment rental rather than ownership.&#8221;
The parent company, Ashtead Group, achieved investment grade ratings (BBB- by S&amp;P in August 2018, Baa3 by Moody), and by Q1 2022, management noted that &#8220;Our decision to invest in Sunbelt Rentals was recently reinforced by their upgraded BBB rating by Fitch.&#8221;
Sunbelt is now Agree 13th largest tenant with over 55 locations, representing 2.3% of base rent.
TJX Companies (Ticker: TJX) Agree relationship with TJX (parent of T.J. Maxx, Marshalls, and HomeGoods) dates back to 2012 when they developed their first T.J. Maxx. The company recognized early that off-price retailers had a sustainable competitive advantage in their treasure-hunt shopping experience and deep vendor relationships.
The insight proved prescient. As management noted in Q2 2017: &#8220;At the same time, in terms of women&#8217;s apparel, you look at T.J. Maxx&#8230;the off-price retailers have thrived.&#8221; By Q4 2017, they were saying: &#8220;the TJX Companies&#8230;is now our #5 tenant. We have a strong bias towards off-price retail and the experience and value proposition that it provides for consumers.&#8221;
Today, TJX is their 6th largest tenant at 3.1% of base rent, and the company continues to expand aggressively. Since 2012, Agree has acquired or developed over 55 TJX locations.
Let me give you a comprehensive look at Agree top tenants, because this portfolio tells the story of a company that has systematically assembled the cream of American retail:
Top 15 Tenants by Annualized Base Rent:
<ol start="1" class="wp-block-list">
<li>Walmart (Ticker: WMT) (5.9%, $38.5M ABR) &#8211; The undisputed king of retail, with the most advanced omni-channel operation in the world. Investment grade (AA from multiple agencies).</li>
<li>Tractor Supply (Ticker: TSCO) (4.9%, $31.8M ABR) &#8211; Dominant rural lifestyle retailer with no national competition. Upgraded to investment grade in 2020 (BBB/Baa1).</li>
<li>Dollar General (Ticker: DG) (4.4%, $28.4M ABR) &#8211; Leading small-box discount retailer serving rural and urban markets where traditional retailers can&#8217;t compete economically. Investment grade (BBB/Baa2).</li>
<li>Best Buy (Ticker: BBY) (3.3%, $21.7M ABR) &#8211; The last major electronics retailer standing, with a successful omni-channel model and services business. Investment grade (BBB/Baa1).</li>
<li>Kroger (Ticker: KR) (3.2%, $20.5M ABR) &#8211; One of America&#8217;s largest supermarket chains with advanced digital capabilities and strong market positions. Investment grade (BBB-/Baa1).</li>
<li>TJX Companies (Ticker: TJX) (3.1%, $20.0M ABR) &#8211; Off-price retail leader with T.J. Maxx, Marshalls, and HomeGoods. Investment grade (A-/A2).</li>
<li>CVS Pharmacy(Ticker: CVS) (3.1%, $19.9M ABR) &#8211; Healthcare-focused pharmacy chain with integrated health services. Investment grade (BBB/Baa2).</li>
<li>Dollar Tree (Ticker: DLTR) (2.8%, $18.3M ABR) &#8211; Fixed-price point retailer with defensive characteristics. Investment grade (BB+/Ba1 &#8211; sub-investment grade but improving).</li>
<li>O&#8217;Reilly Auto Parts (Ticker: ORLY) (2.8%, $18.3M ABR) &#8211; Leading automotive aftermarket parts retailer with strong same-store sales growth and e-commerce resistance. Investment grade (BBB+/Baa1).</li>
<li>Hobby Lobby (2.8%, $18.2M ABR) &#8211; Dominant craft retailer with no direct national competition and products difficult to replicate online. Privately held but with investment-grade quality financials.</li>
<li>Lowe&#8217;s (Ticker: LOW) (2.8%, $17.9M ABR) &#8211; Second-largest home improvement retailer with strong omni-channel capabilities. Investment grade (BBB/Baa2).</li>
<li>Gerber Collision (2.3%, $15.2M ABR) &#8211; Leading auto collision repair chain owned by Boyd Group. Investment grade parent (BBB-/Baa3).</li>
<li>Sunbelt Rentals (2.3%, $15.0M ABR) &#8211; Equipment rental leader owned by Ashtead Group. Investment grade parent (BBB/Baa3).</li>
<li>7-Eleven (2.2%, $14.2M ABR) &#8211; Convenience store leader with defensive location characteristics. Investment grade parent.</li>
<li>Burlington (Ticker: BURL) (2.2%, $14.0M ABR) &#8211; Off-price apparel retailer with strong growth trajectory. Sub-investment grade but improving credit profile.</li>
</ol>
What strikes me about this list is the intentionality behind every single tenant. These are not random retail relationships. They are carefully curated partnerships with companies that have either achieved market dominance, possess unique competitive advantages, or operate in sectors with natural barriers to e-commerce disruption.
Perhaps most impressive is the credit quality: 68.3% of Agree base rent comes from investment-grade tenants. This is not an accident. It is the result of a deliberate strategy to partner with retailers that have strong balance sheets and sustainable business models.
The tenant mix also reveals smart sector allocation:
<ul class="wp-block-list">
<li>Grocery Stores (10.1%): Essential, frequent-visit retailers with omni-channel capabilities</li>
<li>Home Improvement (9.1%): Large-ticket items requiring customer inspection and immediate fulfillment</li>
<li>Convenience Stores (7.8%): Location-dependent businesses with defensive characteristics</li>
<li>Tire &amp; Auto Service (7.8%): Services that require physical presence and specialized equipment</li>
<li>Dollar Stores (7.0%): Serving markets too small for traditional competitors</li>
</ul>
I want to spend a moment on Walmart specifically, because at 5.9% of base rent, they are Agree largest tenant, and this relationship exemplifies everything the company does right.
Walmart is not just surviving the retail apocalypse. They are winning it. The company has built the most sophisticated omni-channel operation in retail, with stores serving as fulfillment centers, pickup locations, and last-mile delivery hubs. Their e-commerce growth has been explosive, but rather than cannibalizing store sales, it is making their physical locations more valuable than ever.
For Agree, Walmart represents the perfect tenant: investment grade credit (AA rating), growing business model, and a real estate strategy that aligns perfectly with the omni-channel future. These are not legacy stores that might become obsolete. They are critical infrastructure for Walmart continued growth.
While the tenant quality is impressive, what really captures my attention is Agree&#8217;s balance sheet. This is what a fortress looks like:
<ul class="wp-block-list">
<li>Investment grade ratings: Baa1 from Moody&#8217;s, BBB+ from S&amp;P</li>
<li>Net debt to recurring EBITDA: 4.9x actual, 3.4x proforma (including forward equity)</li>
<li>Fixed charge coverage ratio: 4.3x</li>
<li>No material debt maturities until 2028</li>
<li>Total liquidity: approximately $2.6 billion</li>
<li>Outstanding forward equity: over $1.3 billion</li>
<li>Revolver capacity: $1.2 billion</li>
</ul>
This gives them tremendous flexibility to take advantage of market dislocations.
With their fortress balance sheet and $2.6 billion in liquidity, Agree is positioned for accelerated growth. Management recently raised their 2025 investment guidance to $1.3-$1.5 billion (up from $1.1-$1.3 billion), reflecting confidence in their ability to find attractive opportunities.
The investment pipeline is enormous: management estimates over 169,000 net lease opportunities across their target sectors, with $92+ billion in opportunities reviewed since 2018. They have been highly selective, investing only $8.0 billion over that period, demonstrating disciplined capital allocation.
In a world where dividend cuts have become commonplace, Agree has paid 159 consecutive monthly dividends with an average AFFO payout ratio of just 75% over the past ten years. The dividend has grown at approximately 6% annually over the past decade, reaching $2.99 per share in 2024.
This is not a yield play built on an unsustainable payout ratio. It is a genuine dividend growth story backed by growing cash flows and conservative financial management.
Here is what I find most compelling about Agree Realty: they have built a dominant position in a sector that most investors still view with skepticism. This creates a sustained competitive advantage. While others avoid retail real estate, Agree gets first look at the best opportunities.
The &#8220;retail apocalypse&#8221; narrative has created a two-tiered market where strong retailers with good real estate get phenomenal terms, while struggling concepts cannot secure financing at any price. Agree benefits from both sides of this dynamic: they get attractive pricing on quality assets while weak competitors are eliminated from their markets.
In a market obsessed with the next shiny object, Agree Realty has quietly built one of the highest-quality REIT portfolios in the market by betting on American retail evolution rather than its demise. They have assembled a collection of retailers that are not just surviving the omni-channel transition. They are thriving because of it.
While others were running from retail real estate, Agree was building relationships with the winners. While others were chasing yield at any cost, Agree was building a sustainable dividend growth engine. While others were leveraging up in good times, Agree was building a fortress balance sheet for all seasons.
This is the kind of contrarian, quality-focused investment that can anchor a portfolio for decades. In a world of uncertainty, Agree Realty offers something increasingly rare: predictable, growing cash flows backed by essential real estate infrastructure and managed by a team with a &#x2A;proven track record of outstanding capital allocation.
Sometimes the best investments are hiding in plain sight, dismissed by the crowd but quietly compounding wealth for those patient enough to see past the headlines.
The insiders in real estate see the opportunity.
You should as well.

Opinion

BURL

DLTR

ORLY

TSCO

Alpha Buying: How This Company Quietly Took Over American Storefronts

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.
What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.
Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.
In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.
&#8220;PBMs corrupt healthcare,&#8221; he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">three major PBMs</a> negotiating over 90% of rebates for commercial insurance plans. 
Warren, in her post, had blamed pharmaceutical giants like Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) for charging Americans the &#8220;highest drug prices in the world&#8221; while paying &#8220;zero dollars in federal taxes.&#8221;
Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.
&#8220;Republicans want to make it worse. I&#8217;m fighting back,&#8221; she declared, sharing <a href="https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html">a</a> CNBC headline and urging action against what she calls a &#8220;rigged tax system.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No. It&#39;s because PBMs corrupt healthcare. Big Pharma wishes they could set their own pricing. They don&#39;t. PBMs control formularies and manipulate prices, in exchange for providing pharma access to patients. It&#39;s how they maximize rebate revenue. In fact, 3 PBMs NEGOTIATE… <a href="https://t.co/GpN4mnzvOM">https://t.co/GpN4mnzvOM</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1935705831930298562?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is ‘Massively Underestimating' This AI Play, Urges Investors To Look Beyond Mag 7</a>
Why It Matters: Cuban has been a c<a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">ritic of the healthcare system</a>, saying that it should be simple. According to him, it&#8217;s become overly complicated by big insurance companies and PBMs.
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and &#8220;Sh–ing on&#8221; on independent pharmacies.
Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>51.15%</td>
<td>9.57%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>14.54%</td>
<td>-6.95%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-39.11%</td>
<td>-36.60%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>1.69%</td>
<td>-4.48%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-0.49%</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.23%</td>
<td>-1.64%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.06%</td>
<td>2.61%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>20.55%</td>
<td>22.94%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-5.44%</td>
<td>-6.27%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.49%</td>
<td>-14.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Insurance

ABBV

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

<a href="https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-checkout=true</a>

EHTH

GOCO

'Senate Republicans to Omit Medicare Advantage Cuts in Tax Bill'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

Press Releases

Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion

Synergy CHC (NASDAQ: SNYR) Taps Coca-Cola Exec to Accelerate Global Expansion of "FOCUSfactor®" Energy Drink – More Stocks Moving Inside

Aetna Supports Industry Actions to Simplify Prior Authorization

CVS Health opens new Workforce Innovation and Talent Center in Chicago

CVS Health to hold second quarter 2025 earnings conference call

Synergy CHC Corp. (NASDAQ: SNYR) Secures Distribution Wins for FOCUSfactor® Supplements and Functional Beverages – More Stocks Inside

Synergy's (NASDAQ: SNYR) "FOCUSfactor" Massive 50,000 Store Expansion Including Walmart (NYSE: WMT) Canada – Alongside MOGO, ELWS, DAIC – Stocks Under $5 to Watch

CVS Health declares quarterly dividend

EngageWell, Rocket Doctor, and CVS Health Foundation Launch Virtual Healthy Aging Program for Adults over 60

Multi-Billion Virtual Healthcare Industry Witnessing Substantial Growth with Rapid Expansion Expected

AMZN

ARTL

BAOS

BMNR

CLRB

COST

CSE:TRUE

DAIC

ELWS

EVGN

IPDN

KLTO

MGNX

MODV

MOGO

NCEW

PLUG

PNPNF

PRSO

SNYR

TDOC

TREIF

TSXV:PNPN

WBUY

WINT

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

CVS Health

CVS Health (CVS) オプション

CVS Health (NYSE:CVS) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル